scholarly journals Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer

2018 ◽  
Vol 36 (11) ◽  
pp. 1088-1095 ◽  
Author(s):  
Alicia K. Morgans ◽  
Yu-Hui Chen ◽  
Christopher J. Sweeney ◽  
David F. Jarrard ◽  
Elizabeth R. Plimack ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Chronic Illness ◽  
Functional Assessment ◽  
Brief Pain Inventory ◽  
Chronic Illness Therapy ◽  
Hormone Sensitive ◽  
Over Time ◽  
Time Point

Purpose Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic hormone-sensitive prostate cancer improves overall survival as compared with androgen deprivation therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+D and those who were treated with ADT alone. Methods Men were randomly assigned to ADT+ D (six cycles) or to ADT alone. QOL was assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P), FACT-Taxane, Functional Assessment of Chronic Illness Therapy-Fatigue, and the Brief Pain Inventory at baseline and at 3, 6, 9, and 12 months. The Wilcoxon signed rank test was used to examine changes over time. Mixed-effect models compared the QOL between arms at each time point. Results Seven hundred ninety men were randomly assigned (ADT+D [n = 397] and ADT[ n = 393]) and completed FACT-P (90% at baseline, 86% at 3 months, 83% at 6 months, 78% at 9 months, and 77% at 12 months). ADT+D patients reported a statistically significant decline in FACT-P at 3 months ( P < .001) but FACT-P did not differ significantly between baseline and 12 months ( P = .38). ADT+D FACT-P scores were significantly lower at 3 months ( P = .02) but significantly higher at 12 months ( P = .04) when compared with ADT FACT-P scores. Differences did not exceed the minimal clinically important difference at any time point. ADT+D patients reported significantly lower Functional Assessment of Chronic Illness Therapy-Fatigue scores at 3 months than did ADT patients ( P < .001). Over time, both arms reported significantly poorer FACT-Taxane scores ( P < .001) when compared with baseline. Brief Pain Inventory scores were similar between arms. Conclusion Although ADT+D was associated with statistically worse QOL at 3 months, QOL was better at 12 months for ADT+D patients than for ADT patients. Both arms reported a similar minimally changed QOL over time, suggesting that ADT+D is not associated with a greater long-term negative impact on QOL.

Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease

2021 ◽  
Author(s):  
Ganit Goren ◽  
Doron Schwartz ◽  
Michael Friger ◽  
Hagar Banai ◽  
Ruslan Sergienko ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Illness ◽  
Functional Assessment ◽  
Stress Reduction ◽  
Crohn Disease ◽  
Psychological Symptoms ◽  
Cognitive Behavioral ◽  
Chronic Illness Therapy ◽  
Relative Change

Abstract Background Patients with Crohn disease have debilitating psychological symptoms, mental fatigue, and poor quality of life. Psychological intervention may improve these symptoms. Methods We performed a randomized parallel-group physician-blinded trial of cognitive-behavioral and mindfulness-based stress reduction (COBMINDEX) on quality of life and psychological symptoms in adults with mild-moderate Crohn disease. COBMINDEX was taught by social workers in one-on-one video conferences over 3 months; quotidian home practice was mandated. Results Fifty-five COBMINDEX and 61 waitlist control patients completed the study; mean age was 33 years and 65% of participants were women. At 3 months, COBMINDEX patients had significantly reduced disease activity (per Harvey-Bradshaw Index score, C-reactive protein level, and calprotectin level), increased quality of life (Short Inflammatory Bowel Disease Questionnaire [SIBDQ] score increased from baseline 41 to 50; P &lt; 0.001), decreased psychological symptoms (Global Severity Index [GSI], 0.98-0.70; P &lt; 0.001), reduced fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue, 26-33; P &lt; 0.001), and increased mindfulness disposition (Freiburg Mindfulness Inventory, 33-38; P &lt; 0.001). Waitlist patients had a significant but small change in Harvey-Bradshaw Index, SIBDQ, and GSI scores, without improvement in fatigue or mindfulness. There were significant correlations (0.02 &gt; P &lt; 0.002) in COBMINDEX patients between baseline SIBDQ, GSI, Freiburg Mindfulness Inventory, and Functional Assessment of Chronic Illness Therapy-Fatigue scores with a relative change (baseline to 3 months) of the SIBDQ score, but none among waitlist patients. Predictors of relative change of the SIBDQ score in COBMINDEX patients included the GSI score (90% quantile; coefficient 0.52; P &lt; 0.001), somatization (90%; 0.20; P = 0.001), depression (75%; 0.16; P = 0.03), and phobic anxiety (75%; 0.31; P = 0.008). Conclusions COBMINDEX was effective in increasing patients’ quality of life and reducing psychological symptoms and fatigue. Patients with severe baseline psychological symptoms benefited the most from COBMINDEX.

scholarly journals Quality of life of women with breast cancer undergoing radiotherapy using the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire

2016 ◽  
Vol Volume 11 ◽  
pp. 1489-1494 ◽  
Author(s):  
Marta Muszalik ◽  
Małgorzata Kołucka –Pluta ◽  
Kornelia Kędziora-Kornatowska ◽  
Joanna Robaczewska
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Chronic Illness ◽  
Functional Assessment ◽  
Chronic Illness Therapy

scholarly journals AB0732 FATIGUE ASSESSMENT IN EGYPTIAN PSORIATIC ARTHRITIS PATIENTS: RELATION TO SERUM INTERLEUKIN 23, DISEASE ACTIVITY AND QUALITY OF LIFE.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1660-1660
Author(s):  
N. Aboeladl ◽  
N. Elsawy ◽  
M. Helal ◽  
M. Elshafei ◽  
N. Lewis
Keyword(s):  
Quality Of Life ◽  
Psoriatic Arthritis ◽  
Chronic Illness ◽  
Disease Activity ◽  
Physical Function ◽  
Functional Assessment ◽  
Fatigue Score ◽  
Chronic Illness Therapy ◽  
Sf 36

Background:Fatigue is a prevalent and fundamental phenomenon in psoriatic arthritis (PsA) patients. It often interferes with physical and social functions and may lead to social withdrawal, long-standing sick leave, disability and loss of work productivity. Fatigue is a prevalent symptom in patients with chronic rheumatic diseases. Cytokines as interleukin IL-23/17 play a pivotal role in the pathogenesis of PsA.Objectives:To assess fatigue in PsA patients and determine its relation to serum IL 23 levels, disease activity, Skin severity, physical function and quality of life (QoL).Methods:Fifty PsA patients and 46 matched healthy controls were included in this study. Skin severity based on the Psoriasis Area and Severity Index (PASI), the Disease Activity index for Psoriatic Arthritis (DAPSA) and the Functional Assessment of Chronic Illness Therapy (FACIT-F) were assessed. Physical function was assessed by the Health Assessment Questionnaire Disability Index (HAQ-DI) and health-related QoL was assessed using the Short Form Health Survey (SF-36), Psoriatic Arthritis QoL (PsAQoL) and the Dermatology Life Quality Index (DLQI). Serum IL-23 levels were measured in the studied groups.Results:The study included 23 (46%) females and 27 (54%) males with a mean age of 42.78±12.33 years. The mean serum IL-23 level was significantly higher in PsA patients (50.89 ±13.86 pg/ml) than in controls (43.88 ± 6.34 pg/ml) (p=0.006). The FACIT score ranged from 2-41. Severe fatigue (score <30) was reported in 27 (54%) PsA patients. There were significant correlations between FACIT-F and (DAPSA, PASI, HAQ-DI, PsAQoL, DLQI and SF-36). No significant correlations could be detected between FACIT-F and serum levels of IL-23 and CRP.Conclusion:Fatigue was a frequent complaint in PsA patients. There was a mutual negative impact between fatigue and each of PsA joint disease activity and physical function and it worsened the QoL. Fatigue was worsened with increased severity of skin PsO. Although serum level of IL-23 was significantly elevated in PsA patients than the controls, it wasn’t correlated with fatigue score. Hence IL-23 can’t be considered a biomarker for fatigue severity.References:[1]Chandran V, Bhella S, Schentag C, Gladman DD. Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007; 66(7):936.[2]Mortada M, Abdul-Sattar A, Gossec L. Fatigue in Egyptian patients with rheumatic diseases: a qualitative study. Health Qual Life Outcomes 2015; 13:134.[3]Krajewska-Wlodarczyk M, Owczarczyk-Saczonek A, Placek W. Fatigue - an underestimated symptom in psoriatic arthritis. Reumatologia 2017; 55(3):125-30.[4]Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Ann Rheum Dis 2017; 76(1):203-7.[5]Reygaerts T, Mitrovic S, Fautrel B, Gossec L. Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis. Joint Bone Spine 2018; 85(4):405-10.Table.Correlation between FACIT-F score and different parameters in patients groupFACIT-FrspDAPSA-0.365*0.009*PASI-0.424*0.002*HAQ-DI-0.464*0.001*PsAQoL-0.633*<0.001*DLQI-0.492*<0.001*SF-360.600*<0.001*CRP-0.1670.247Serum IL-23 levels-0.1830.204rs: Spearman coefficient, *: Statistically significant at p ≤ 0.05Figure. Correlation between FACIT-F and DAPSA in the studied PsA patients.Acknowledgments:I am deeply indebted to my late Professor Abdelmoniem Helal for his expert guidance and keen interest throughout the work.Thanks to My parents and Husband.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document